Price Don’t Lie: Crocs, Inc. Stock Is At 1 Year Low Now

Price Don't Lie: Crocs, Inc. Stock Is At 1 Year Low Now

The stock of Crocs, Inc. (NASDAQ:CROX) hit a new 52-week low and has $7.06 target or 9.00% below today’s $7.76 share price. The 7 months bearish chart indicates high risk for the $582.93M company. The 1-year low was reported on Nov, 9 by If the $7.06 price target is reached, the company will be worth $52.46M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 733,463 shares traded hands or 10.21% up from the average. Crocs, Inc. (NASDAQ:CROX) has declined 12.35% since April 7, 2016 and is downtrending. It has underperformed by 17.13% the S&P500.

Crocs, Inc. (NASDAQ:CROX) Ratings Coverage

Out of 7 analysts covering Crocs (NASDAQ:CROX), 2 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 29% are positive. Crocs has been the topic of 12 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The stock of Crocs, Inc. (NASDAQ:CROX) earned “Buy” rating by Sterne Agee CRT on Friday, August 14. The company was upgraded on Tuesday, May 10 by Sterne Agee CRT. The stock of Crocs, Inc. (NASDAQ:CROX) earned “Neutral” rating by B. Riley & Co on Thursday, October 1. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, October 1. As per Monday, November 9, the company rating was maintained by Monness Crespi & Hardt. The company was downgraded on Tuesday, October 27 by Sterne Agee CRT. The stock has “Neutral” rating given by Piper Jaffray on Thursday, October 1. The stock has “Neutral” rating given by Susquehanna on Friday, August 12. The stock of Crocs, Inc. (NASDAQ:CROX) earned “Buy” rating by Piper Jaffray on Tuesday, August 11. As per Wednesday, April 27, the company rating was downgraded by Stifel Nicolaus.

According to Zacks Investment Research, “Crocs, Inc. is a rapidly growing designer, manufacturer and marketer of footwear for men, women and children under the CROCS brand. All of the Company’s footwear products incorporate its proprietary closed-cell resin material, which the Company believes represents a substantial innovation in footwear comfort and functionality. The Company’s proprietary closed-cell resin, which it refers to as Croslite enables Crocs to produce a soft and lightweight, non-marking, slip and odor-resistant shoe. These unique properties make the Company’s footwear ideal for casual wear, as well as for recreational uses such as boating, hiking, fishing and gardening, and have enabled Crocs to successfully market its products to a broad range of consumers.”

Insitutional Activity: The institutional sentiment decreased to 0.9 in 2016 Q2. Its down 0.15, from 1.05 in 2016Q1. The ratio worsened, as 29 funds sold all Crocs, Inc. shares owned while 43 reduced positions. 17 funds bought stakes while 48 increased positions. They now own 71.30 million shares or 0.46% less from 71.63 million shares in 2016Q1.
State Board Of Administration Of Florida Retirement Sys last reported 0% of its portfolio in the stock. Us Bank De holds 32,623 shares or 0% of its portfolio. Lpl owns 28,629 shares or 0% of their US portfolio. Schwab Charles Management Incorporated has invested 0.01% of its portfolio in Crocs, Inc. (NASDAQ:CROX). Manufacturers Life Insur The holds 51,102 shares or 0% of its portfolio. Prudential Financial has 0% invested in the company for 177,795 shares. The Massachusetts-based North Run Lp has invested 3.53% in Crocs, Inc. (NASDAQ:CROX). Qs Invsts Limited Liability Com holds 0% of its portfolio in Crocs, Inc. (NASDAQ:CROX) for 27 shares. Goldman Sachs Group Inc has invested 0% of its portfolio in Crocs, Inc. (NASDAQ:CROX). Ironwood Inv Ltd Liability last reported 0.62% of its portfolio in the stock. Citigroup Inc has 5,122 shares for 0% of their US portfolio. Deutsche National Bank & Trust Ag last reported 272,709 shares in the company. Da Davidson Company has 0% invested in the company for 300 shares. Credit Suisse Ag holds 0% of its portfolio in Crocs, Inc. (NASDAQ:CROX) for 128,778 shares. Etrade Cap Limited Liability Co has invested 0.06% of its portfolio in Crocs, Inc. (NASDAQ:CROX).

Insider Transactions: Since August 24, 2016, the stock had 1 buy, and 0 selling transactions for $66,371 net activity. Shares for $66,371 were bought by Teffner Carrie W. on Wednesday, August 24.

Another recent and important Crocs, Inc. (NASDAQ:CROX) news was published by which published an article titled: “Earnings Reaction History: Crocs, Inc., 42.9% Follow-Through Indicator, 9.1 …” on November 09, 2016.

CROX Company Profile

Crocs, Inc., incorporated on April 15, 2005, is engaged in the design, development, manufacturing, across the world marketing and distribution of casual lifestyle footwear and accessories for men, women and children. The Company’s divisions include Americas, Asia Pacific and Europe. The Company’s products include footwear and accessories that utilize its closed-cell resin, called Croslite, as well as casual lifestyle footwear that use a range of materials. It sells its products in over 60 countries through domestic and international retailers and distributors, and directly to clients through its company-operated retail stores, outlets, Webstores and kiosks. The Firm markets its products through a range of channels, including family footwear stores, department stores, department stores, sporting goods stores and traditional footwear retailers, as well as a range of specialty and independent retail channels, and through the Internet. The Firm operates approximately 270 global retail stores, 190 global outlet stores and 100 global kiosks and store-in-stores. The Firm offers a range of footwear products, including clogs, sandals, wedges, flats, sneakers and boots.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment